Gland Pharma Stock Screener | Share Price & Fundamental Analysis
GLAND
Pharmaceuticals
Screen Gland Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1698.20
▼
-17.60 (-1.03%)
Share Price BSE
₹1698.15
▼
-15.80 (-0.92%)
Market Cap
₹28,257.37 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.97
EPS (TTM)
₹42.40
Dividend Yield
1.05%
Debt to Equity
0.04
52W High
₹2102.10
52W Low
₹1392.80
Operating Margin
24.00%
Profit Margin
12.73%
Revenue (TTM)
₹1,469.00
EBITDA
₹392.00
Net Income
₹187.00
Total Assets
₹11,225.00
Total Equity
₹9,151.00
Gland Pharma Share Price History - Stock Screener Chart
Screen GLAND historical share price movements with interactive charts. Analyze price trends and patterns.
Gland Pharma Company Profile - Fundamental Screener
Screen Gland Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLAND shares.
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
SRINIVAS SADU
ISIN
INE068V01023
Website
https://www.glandpharma.com
Gland Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GLAND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 11,225 | 10,661 | 8,778 | 7,834 | 6,496 | 4,086 |
| Current Assets | 6,783 | 5,645 | 6,901 | 5,852 | 5,124 | 2,846 |
| Fixed Assets | 4,147 | 3,947 | 1,571 | 1,502 | 954 | 968 |
| Liabilities | ||||||
| Total Liabilities | 11,225 | 10,661 | 8,778 | 7,834 | 6,496 | 4,086 |
| Current Liabilities | 509 | 539 | 90 | 94 | 80 | 81 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 9,151 | 8,724 | 7,959 | 7,158 | 5,903 | 3,646 |
| Share Capital | 17 | 17 | 17 | 16 | 16 | 16 |
| Reserves & Surplus | 9,134 | 8,707 | 7,942 | 7,141 | 5,887 | 3,631 |
Screen GLAND income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,469 | 1,563 | 1,571 | 1,580 | 1,453 | 1,466 | 1,443 | 824 | 1,246 | 1,427 | 1,583 | 1,168 | 931 | 1,110 | 1,000 |
| Expenses | 1,077 | 1,138 | 1,173 | 1,179 | 1,137 | 1,109 | 1,024 | 673 | 915 | 1,049 | 1,189 | 755 | 587 | 748 | 649 |
| EBITDA | 392 | 425 | 398 | 401 | 316 | 357 | 418 | 151 | 332 | 377 | 394 | 414 | 344 | 363 | 351 |
| Operating Profit % | 24.00% | 24.00% | 21.00% | 23.00% | 19.00% | 21.00% | 26.00% | 14.00% | 24.00% | 24.00% | 23.00% | 32.00% | 32.00% | 28.00% | 31.00% |
| Depreciation | 96 | 101 | 106 | 93 | 92 | 94 | 96 | 38 | 65 | 81 | 105 | 31 | 35 | 37 | 38 |
| Interest | 7 | 12 | 8 | 10 | 6 | 6 | 23 | 2 | 5 | 6 | 5 | 2 | 1 | 2 | 3 |
| Profit Before Tax | 288 | 313 | 284 | 298 | 218 | 257 | 299 | 111 | 261 | 290 | 283 | 381 | 309 | 324 | 311 |
| Tax | 102 | 97 | 100 | 106 | 75 | 93 | 95 | 33 | 67 | 96 | 91 | 95 | 79 | 83 | 79 |
| Net Profit | 187 | 216 | 184 | 192 | 144 | 164 | 205 | 79 | 194 | 194 | 192 | 286 | 229 | 241 | 232 |
| EPS | 11.32 | 13.08 | 11.15 | 11.68 | 8.73 | 9.93 | 12.42 | 4.78 | 11.79 | 11.78 | 11.65 | 17.40 | 13.93 | 14.65 | 14.08 |
Gland Pharma Cash Flow Screener - Liquidity Fundamentals
Screen GLAND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 915 | 997 | 364 | 791 | 605 | 701 |
| Investing Activities | 1,718 | -1,749 | 1,211 | -999 | -1,520 | -761 |
| Financing Activities | -434 | -799 | 15 | 35 | 1,239 | -7 |
| Net Cash Flow | 2,199 | -1,552 | 1,590 | -174 | 323 | -67 |
Screen GLAND shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 57.86% | 57.86% |
| FII Holding | 7.91% | 7.39% | 6.90% | 5.04% | 4.47% | 6.88% | 3.59% | 0.00% |
| DII Holding | 32.64% | 32.85% | 33.27% | 34.80% | 35.37% | 32.83% | 25.23% | 23.14% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 2.57% | 2.91% | 2.99% | 3.30% | 3.28% | 3.33% | 3.28% | 3.79% |
| Other Holding | 5.06% | 5.02% | 5.01% | 5.04% | 5.04% | 5.12% | 10.04% | 15.22% |
| Shareholder Count | 97,151 | 110,671 | 113,788 | 121,075 | 122,358 | 122,665 | 122,375 | 136,021 |
Gland Pharma Dividend Screener - Share Yield Analysis
Screen GLAND dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹18.00 | 1.05% |
| 2024-March | ₹20.00 | 1.26% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Gland Pharma Index Membership - Market Screener Classification
Screen GLAND by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Gland Pharma Market Events Screener - Corporate Actions
Screen GLAND market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 0.59% |
| 2025-08-28 | 2025-08-28 | Annual General Meeting | NA | 29.92% |
| 2025-08-14 | 2025-08-14 | Dividend | ₹ 18.00 /share | 31.41% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -0.90% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 4.61% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -8.51% |
| 2024-11-04 | 2024-11-04 | Quarterly Result Announcement | NA | -1.82% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 2.71% |
| 2024-08-16 | 2024-08-16 | Dividend | ₹ 20.00 /share | 8.78% |
Gland Pharma Competitors Screener - Peer Comparison
Screen GLAND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Gland Pharma Company Announcements - News Screener
Screen GLAND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-03 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-03 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-17 | Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-09-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-09-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-08-28 | Announcement under Regulation 30 (LODR)-Change in Management | View |